SABS — SAB Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $258.40m
- $158.97m
Brief: SAB Biotherapeutics Diversitab Platform Proves To Develop Anti-Idiotype Antibodies
Brief: SAB Biotherapeutics Announces $7.9 Million Private Placement Of Common Stock
SAB Biotherapeutics rises after H.C.Wainwright initiates with 'buy' rating
Brief: Sab Biotherapeutics Initiates Ind-Enabling Glp Toxicology Study For Sab-142, Novel Immunotherapeutic For Type 1 Diabetes
Brief: Sab Biotherapeutics Provides Company Update For Q3 2022 Financial Results
SAB Biotherapeutics gains on manufacturing agreement with Emergent
Brief: Sab Biotherapeutics Announces Exclusive Manufacturing Partnership With Emergent Biosolutions
Brief: Sab Biotherapeutics Says Received Notice Of Failure To Satisfy Continued Listing Rule
Brief: SAB Biotherapeutics Unveils New Data At Isirv Options XI Conference Validating SAB-176 Proof Of Concept In Reducing Viral Load And Improving Symptoms Of Influenza And Showing SAB-185 Effective Against Multiple Covid-19 Variants Including Omicron
Brief: SAB Biotherapeutics To Present New Data At ISIRV Options XI Conference On SAB-185's Effectiveness Against Multiple COVID-19 Variants
Brief: Sab Biotherapeutics Says Cash And Cash Equivalents Were $16.6 Mln As Of June 30
Brief: Sab Biotherapeutics Advancing Pipeline And Expands Into Treatment For C. Diff. As Dod Contract Winds Down
Brief: Sab Biotherapeutics Elects Scott Giberson To Board Of Directors
Brief: Sab Biotherapeutics Announces Appointment Of Alexandra Kropotova As Chief Medical Officer
U.S. STOCKS ON THE MOVE-Didi Global, Apple Inc, Tesla Inc
Brief: SAB Biotherapeutics Reports Q1 EPS Of $0.02
Brief: SAB Biotherapeutics Provides Company Update And Reports Full Year 2021 Financial Results
U.S. STOCKS ON THE MOVE-Hewlett Packard, Pfizer, coal stocks
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM